At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Mar 17, 2026 at 22:46 ET
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30 per share, raising $250 million in gross proceeds. The company plans to use the funds primarily for the development of its lead asset Varseta-M and other pipeline programs, with a 30-day over-allotment option for up to an additional 7,075,471 shares.
- CytomX raised $250 million in gross proceeds through a public offering.
- Offering includes 45,990,567 common shares and pre-funded warrants for 1,179,245 shares, priced at $5.30 per share.
- Underwriters have a 30-day option to purchase up to an additional 7,075,471 shares.
- Proceeds will fund development of Varseta-M (CX-2051) and other pipeline assets, plus general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access